Natural Compound

Lutein

β,ε-Carotene-3,3'-diol (Lutein)

Evidence TierAWADA NOT PROHIBITED

tuneTypical Dose

10-20 mg per day

watchEffect Window

3-6 months for meaningful MPOD increase. Ongoing protection with continued use.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Lutein is a carotenoid concentrated in the macula and brain. It is used for eye health, visual performance, and as part of strategies to slow age-related macular degeneration progression.

Evidence shows lutein increases macular pigment density and improves contrast sensitivity and glare tolerance. Combination trials support slowed macular degeneration progression when used with related antioxidants in specific formulas. Minority evidence suggests cognitive benefits in older adults due to brain accumulation. Effects are most evident with long-term use and low baseline dietary carotenoid intake.

Xanthophyll carotenoid that accumulates in the macula, filtering high-energy blue light and acting as a direct retinal antioxidant.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Slows AMD progression when combined with zeaxanthin in AREDS2 formula
  • Increases macular pigment optical density (MPOD)

Secondary Outcomes

  • Improves contrast sensitivity and glare recovery
  • Emerging neuroprotective benefits for cognitive function

Safety

Contraindications and Interactions

Contraindications

  • None established

Side effects

  • Harmless skin yellowing (carotenodermia) at very high doses

Interactions

  • Orlistat/cholestyramine may reduce absorption
  • Beta-carotene competes for absorption

Avoid if

  • Smokers taking concurrent high-dose beta-carotene

Evidence

Study-level References

lutein-SRC-001RCT (Multicenter, double-blind)
Sourceopen_in_new

Chew EY, et al. "Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial." JAMA. 2013.

Population: Adults with intermediate/advanced AMD

Key findings: The addition of Lutein (10mg) and Zeaxanthin (2mg) to the AREDS formulation resulted in a safe and effective reduction in the progression to advanced AMD, establishing it as the standard of care.

Paper content

The addition of Lutein (10mg) and Zeaxanthin (2mg) to the AREDS formulation resulted in a safe and effective reduction in the progression to advanced AMD, establishing it as the standard of care.

lutein-SRC-002Systematic review and network meta-analysis of randomized controlled trials.
Sourceopen_in_new

Hu W, Seah V, Huang V, Kim JE. Effect of Antioxidant Supplementation on Macular Pigment Optical Density and Visual Functions: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2024;15(5):100216. doi:10.1016/j.advnut.2024.100216. PMID:38582248.

Population: Adults receiving dietary antioxidant supplements across 60 studies (38 included in quantitative synthesis).

Dose protocol: Eight antioxidant strategies including lutein, zeaxanthin, and fatty acid combinations across 60 RCTs

Key findings: All antioxidant groups significantly increased MPOD and contrast sensitivity. Lutein plus zeaxanthin plus fatty acid combination ranked highest for MPOD improvement.

Notes: Network meta-analysis confirms broad MPOD benefit of lutein-containing supplements.

Paper content

This network meta-analysis of 60 RCTs compared eight antioxidant supplementation strategies for their effects on macular pigment optical density and visual functions. All antioxidant groups significantly increased MPOD and contrast sensitivity at low spatial frequency compared to placebo. The lutein plus zeaxanthin plus fatty acid combination ranked highest for MPOD improvement. Visual acuity and photostress recovery benefits were limited to specific combinations. Authors note that findings should be interpreted with caution due to low quality of evidence across included trials.

Guides

Setup

Help